127 related articles for article (PubMed ID: 16856889)
1. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.
Hess G; Wagner V; Kreft A; Heussel CP; Huber C
Br J Haematol; 2006 Sep; 134(5):544-5. PubMed ID: 16856889
[No Abstract] [Full Text] [Related]
2. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).
Sobas MA; Alonso Vence N; Diaz Arias J; Bendaña Lopez A; Fraga Rodriguez M; Bello Lopez JL
Ann Hematol; 2010 Feb; 89(2):217-9. PubMed ID: 19636554
[No Abstract] [Full Text] [Related]
3. Acute humoral rejection in a lung recipient: reversion with bortezomib.
Neumann J; Tarrasconi H; Bortolotto A; Machuca T; Canabarro R; Sporleder H; Fernandes S; Schio S; Costa C; Camargo S; Sanchez L; Camargo J; Perin F; Felicetti J; Michelon T
Transplantation; 2010 Jan; 89(1):125-6. PubMed ID: 20061929
[No Abstract] [Full Text] [Related]
4. Response to bortezomib in refractory type I cryoglobulinemia.
Talamo G; Claxton D; Tricot G; Fink L; Zangari M
Am J Hematol; 2008 Nov; 83(11):883-4. PubMed ID: 18756542
[No Abstract] [Full Text] [Related]
5. Bortezomib in lung transplantation: a promising start.
Neumann J; Schio S; Tarrasconi H; Bortolotto A; Costa C; Machuca T; Camargo S; Sanchez L; Michelon T; Canabarro R; Sporleder H; Fernandes S; Camargo J; Perin F; Felicetti J
Clin Transpl; 2009; ():421-4. PubMed ID: 20524308
[No Abstract] [Full Text] [Related]
6. Bortezomib in the treatment of antibody-mediated rejection--a report of 3 cases.
Mai HL; Cesbron A; Brouard S; Blanchol G; Cantarovich D; Dantal J; Hourmant M; Lino M; Meurette A; Gosselin M; Abbadie O; Soulillou JP; Giral M
Clin Transpl; 2009; ():361-8. PubMed ID: 20524299
[No Abstract] [Full Text] [Related]
7. [Use of proteasome inhibitors in the treatment of patients with multiple myeloma].
Rukavitsyn OA
Ter Arkh; 2006; 78(10):40-4. PubMed ID: 17180936
[No Abstract] [Full Text] [Related]
8. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance.
Ojeda-Uribe M; Caron C; Itzhar-Baikian N; Debliquis A
Am J Hematol; 2010 May; 85(5):396. PubMed ID: 20425807
[No Abstract] [Full Text] [Related]
10. Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.
Spizzo G; Mitterer M; Gunsilius E
Br J Haematol; 2010 Jul; 150(2):235-7. PubMed ID: 20346005
[No Abstract] [Full Text] [Related]
11. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants.
Weston M; Rolfe M; Haddad T; Lopez-Cepero M
Clin Transpl; 2009; ():393-9. PubMed ID: 20524304
[TBL] [Abstract][Full Text] [Related]
12. Clonal deletion with bortezomib followed by low or no maintenance immunosuppression in renal allograft recipients.
Trivedi HL; Terasaki PI; Feroz A; Vanikar AV; Trivedi VB; Khemchandani SI; Dave SD; Shankar V; Modi PR; Kaneku H; Idica A; Everly MJ
Transplantation; 2010 Jul; 90(2):221-2. PubMed ID: 20644455
[No Abstract] [Full Text] [Related]
13. The role of bortezomib in the treatment of lymphoma.
Barr P; Fisher R; Friedberg J
Cancer Invest; 2007 Dec; 25(8):766-75. PubMed ID: 18058474
[TBL] [Abstract][Full Text] [Related]
14. Use of bortezomib as adjunctive therapy for densensitization in combined heart and kidney transplantation--a case report.
Patel JK; Everly MJ; Kittleson M; Kobashigawa JA
Clin Transpl; 2009; ():347-9. PubMed ID: 20524297
[No Abstract] [Full Text] [Related]
15. A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
Filosto M; Rossi G; Pelizzari AM; Buzio S; Tentorio M; Broglio L; Mancuso M; Rinaldi M; Scarpelli M; Padovani A
J Neurol Sci; 2007 Dec; 263(1-2):40-3. PubMed ID: 17612569
[TBL] [Abstract][Full Text] [Related]
16. The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model.
He XP; Li XX; Bi YW; Yue WM; Sun WY; Pang XY; Gu XH
Transplant Proc; 2008 Jun; 40(5):1722-6. PubMed ID: 18589180
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib rescue in refractory acute humoral rejection--report of a case.
Shapiro R; Basu A; Zeevi A; Lunz J; Mapara M; Randhawa P; Morgan C; Tan HP; Sharma V
Clin Transpl; 2009; ():431-2. PubMed ID: 20524310
[No Abstract] [Full Text] [Related]
18. Successful desensitization in a crossmatch positive living-related kidney transplant recipient using a bortezomib-based protocol.
Zhu L; Lin Z; Xiang Y; Liu S; Chen G
Clin Transpl; 2009; ():359-60. PubMed ID: 20524298
[TBL] [Abstract][Full Text] [Related]
19. Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Timurağaoğlu A; Ozkaynak C; Tuzuner S; Bostan F; Undar L
Acta Haematol; 2007; 118(4):203-4. PubMed ID: 17992010
[No Abstract] [Full Text] [Related]
20. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
